Aminothiadiazole in the treatment of advanced leiomyosarcoma of the uterine corpus. A Gynecologic Oncology Group study

Am J Clin Oncol. 1995 Oct;18(5):397-9. doi: 10.1097/00000421-199510000-00007.

Abstract

Aminothiadiazole was used to treat 21 patients with metastatic or recurrent leiomyosarcoma of the uterus. All patients received a starting dose of aminothiadiazole of 125 mg/m2 intravenously (30-to-45-minute infusion), which was repeated at weekly intervals. All patients also took allopurinol 300 mg per day orally to prevent hyperuricemia, a side effect of aminothiadiazole. Five patients (25%) had stable disease but there were no objective responses. Toxicity was generally mild with this regimen. There was no life-threatening toxicity and only three episodes of severe toxicity. One patient experienced both grade 3 leukopenia and thrombocytopenia, while another patient had grade 3 nausea and vomiting. Further studies in this disease are not planned.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Female
  • Humans
  • Leiomyosarcoma / drug therapy*
  • Leiomyosarcoma / secondary
  • Middle Aged
  • Thiadiazoles / administration & dosage
  • Thiadiazoles / adverse effects
  • Thiadiazoles / therapeutic use*
  • Uterine Neoplasms / drug therapy*
  • Uterine Neoplasms / pathology

Substances

  • Antineoplastic Agents
  • Thiadiazoles
  • 2-amino-1,3,4-thiadiazole